Primary large B-cell lymphoma of the bone marrow.
Hishizawa
Masakatsu
M
Department of Haematology, Osaka Red Cross Hospital, Tennouji, Osaka, Japan. hishiza@kuhp.kyoto-u.ac.jp
Okamoto
Kohei
K
Chonabayashi
Kazuhisa
K
Kaneko
Hitomi
H
Watanabe
Mitsumasa
M
Tsudo
Mitsuru
M
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019046:Bone Marrow Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000601:surgery; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis* / Q000188:drug therapy / Q000601:surgery; D008279:Magnetic Resonance Imaging; D008297:Male; D036102:Peripheral Blood Stem Cell Transplantation; D049268:Positron-Emission Tomography; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone